November 28, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231:

Pameia Gaveπ

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

#### NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

David Botstein, Belmont, California Audrey Goddard, San Francisco, California David A. Lawrence, San Francisco, California Diane Pennica, Burlingame, California Margaret Ann Roy, San Francisco, California William I. Wood, Hillsborough, California

Title:

CARDIOTROPHIN-1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR

### 1. Type of Application

•	1	This app	lication is	for an	original,	non-provi	sional a	application.
	4				· ·			1 1

[]	This is a non-provisional application claiming priority to provisional application no. $\_$ , file
	, the entire disclosure of which is hereby incorporated by reference.

[ X ]	This is a [ ] continuation-in-part [ X] continuation [ ] divisional application
- •	claiming priority to application Serial Number 09/234,730, filed January 21, 1999, which is
	a non-provisional application of Application Serial No. 09/033,114, filed March 2, 1998, which
	is a continuation of U.S. Application Serial No. 08/733,850 filed October 18, 1996, now
	abandoned, which is a continuation of U.S. Application Serial No. 08/443,129 filed May 17,
	1995, issued May 6, 1997 as U.S. Patent No. 5,627,073, which is a divisional application of
	U.S. Application Serial No. 08/286,304 filed August 5, 1994, issued November 5, 1996 as
	U.S. Patent No. 5,571,893, which is a continuation-in-part of U.S. Application Serial No.
	08/233,609 filed April 25, 1994, issued July 9, 1996 as U.S. Patent No. 5,534,615, and to
	U.S. Provisional Application Serial No. 60/113,296, filed December 22, 1998, the entire
	disclosure of which is hereby incorporated by reference.
	disclosure of willott is hereby incorporated by telefolice:

that had have the first to the first that the first that he

2.	Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  (Non-provisional)  61 pages of specification 2 pages of claims 1 page(s) of abstract 13 sheet(s) of drawings [X] formal [] informal 5 pages of sequence listing
3.	Declaration or Oath
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)  An executed declaration of the inventor(s) [] is enclosed [] will follow.
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted)  X A copy of the unsigned declaration/oath as filed in the prior application is enclosed (37 CFR 1.63(d)), as well as a copy of the executed declaration/oath as filed in the parent application on November 22, 2000.
	(for Cont./Div. where inventor(s) being deleted)  A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
4.	Assignment
	(for new and CIP applications)  An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.
	(for cont./div.)  X The prior application is assigned of record to Genentech, Inc.
5.	Amendments (for continuation and divisional applications)
X	X Cancel in this application original claims 2, 4-23 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	X A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

# Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

	_X_	Amend the specification by inserting before the first line the sentence:
	This i	s a
	<u>x</u>	non-provisional application continuation divisional continuation-in-part
$\cap$	of co-p	ending application(s)
	<u>X</u>	Serial Number 09/234,730, filed January 21, 1999, which is a non-provisional application of Application Serial No. 09/033,114, filed March 2, 1998, which is a continuation of U.S. Application Serial No. 08/733,850 filed October 18, 1996, now abandoned, which is a continuation of U.S. Application Serial No. 08/443,129 filed May 17, 1995, issued May 6, 1997 as U.S. Patent No. 5,627,073, which is a divisional application of U.S. Application Serial No. 08/286,304 filed August 5, 1994, issued November 5, 1996 as U.S. Patent No. 5,571,893, which is a continuation-in-part of U.S. Application Serial No. 08/233,609 filed April 25, 1994, issued July 9, 1996 as U.S. Patent No. 5,534,615, and to U.S. Provisional Application Serial No. 60/113,296, filed December 22, 1998, which applications are incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120
		International Application _ filed on _ which designated the U.S., which application(s) is(are)
IJ		incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120
		provisional application No filed, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119

## 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		CLAIN	S FOR FEE CA	ALCULATION		
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)	
		entra de la companya			\$710.00	
Total Claims	14	- 20 =	0	X \$18.00	\$0.00	
Independent Claims	2	- 3=	0	X \$80.00	\$0.00	
	Multiple dependent claim(s), if any			+ \$270.00	\$0.00	
			Fil	ing Fee Calculation	\$710.00	

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$710.00. A duplicate copy of this transmittal is enclosed.

## 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet** is enclosed.

#### 9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- [] A new Power of Attorney or authorization of agent.
- [] Other:

# 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

A petition, fee and/or response has been filed to extend the term in
the pending prior application until
 A copy of the petition for extension of time in the <i>prior</i> application
is attached.

the tree terms were some some many and the form that the first the time that the

# 11. Correspondence Address:

X Address all future communications to:

Attn: Deirdre L. Conley

Respectfully submitted, GENENTECH, INC.

Date: November 28, 2000

Delrdre L. Conley Reg. No. 36,487

Telephone No. (650) 225-2066

**₩₩₩₩₩₩** 

PATENT TRADEMARK OFFICE